Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?
Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff? Yahoo Finance
Covered in this story
Analyst targets on Merck & Co.
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
- Cantor Fitzgerald: $142 → $145 by Oct 2027 · Neutral via MarketBeat
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 33 stories mentioning Merck & Co., the earliest published 16 Jul 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.